15P Intracranial (IC) efficacy of ivonescimab (ivo) plus chemotherapy (chemo) in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-resistant, EGFR-mutated non-small cell lung cancer (NSCLC) in the HARMONi study
Conclusions:In real-world, ami frequently caused early-onset AEs, including G3 events.Prophylactic strategies need to be fully implemented in clinical practice to mitigate toxicity.
Authors
- J.W. Goldman
- Junmin Li (ORCID: https://orcid.org/0000-0003-0775-0878)
- Lori Styles
- HL West
- W. Li
- X. Le
- Y. Luo
- A. Passaro
- L. Bazhenova
- J. Laskin
- F. Cappuzzo
- D. Rodriguez-Abreu
- R. Yang
- A. Calles Blanco
- N. Girard
- G. Lo Russo
- S. Popat
- N. Leighl
- W. Fang
- L. Zhang
Institutions
- Universidad de Las Palmas de Gran Canaria (ES)
- Royal Marsden NHS Foundation Trust (GB)
- The University of Texas MD Anderson Cancer Center (US)
- Sun Yat-sen University (CN)
- Hospital Universitario Insular de Gran Canaria (ES)
- UCLA Health (US)
- UC San Diego Health System (US)
- Princess Margaret Cancer Centre (CA)
- Hospital General Universitario Gregorio Marañón (ES)
- Hunan Cancer Hospital (CN)
- Royal Marsden Hospital (GB)
- Vyne Therapeutics (United States) (US)
- Sun Yat-sen University Cancer Center (CN)
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
- European Institute of Oncology (IT)
- Institut Curie (FR)
Publication Details
- Journal
- ESMO Open
- Published
- 2026-03-17
- DOI
- https://doi.org/10.1016/j.esmoop.2026.106322
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00